SEC’s Busy Week: Schering Notified Of Potential Suit; Waksal Expands Plea
Executive Summary
SEC's crackdown on corporate accounting and investor communications is reaching deeper into the pharmaceutical sector
You may also be interested in...
King Medicaid Rebate Data Sought By SEC; Subpoena Includes Altace Rebates
The Securities & Exchange Commission is asking King to provide information about its Medicaid rebate calculations as part of a broad subpoena disclosed by the company March 11
FDA/SEC Regulatory Coordination Talks Await New Securities Chairman
FDA and the Securities & Exchange Commission are deferring discussions about ideas for closer cooperation pending the appointment of a new SEC chairman
Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
The Philadelphia U.S. Attorney's selection of Virginia Gibson to succeed Jim Sheehan as its Civil Division chief suggests continuity in the office's prescription drug fraud and kickback investigations